About Berry Genomics
Berry Genomics is a company based in Beijing (China) founded in 2010. Berry Genomics has raised $16 million across 3 funding rounds from investors including Qiming Venture Partners and Legend Capital. The company has 1,400 employees. Berry Genomics operates in a competitive market with competitors including Natera, SYNLAB, Rejuvenate Bio, Novogene Corporation and Progenity, among others.
- Headquarter Beijing, China
- Employees 1,400
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website berrygenomics.com
- Legal Name Berry Genomics Co. Ltd. Class A
- Annual Revenue$132.51 M (USD)-13.42as on Dec 31, 2025
- Net Profit-$28.12 M (USD)-2.29as on Dec 31, 2025
- EBITDA-$11.22 M (USD)-267.72as on Dec 31, 2025
- Total Equity Funding$16M (USD)
in 3 rounds
- Latest Funding Round$16M (USD), Series B
Apr 2015
- InvestorsQiming Venture Partners
& 1 more
- Employee Count1,400
Funding Insights of Berry Genomics
Berry Genomics has successfully raised a total of $16M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $16 million completed in April 2015. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $16M
- Total Rounds 3
- Last Round Series B — $16M
- Investors Count 2
All 3 funding rounds of Berry Genomics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2015 | $16M | Series B | – | – | |
| Oct 2013 | – | Series B | – | Legend Capital | – |
| Jun 2011 | – | Series A | – | – |
2 investors in total: 2 institutional.
Investors in Berry Genomics
Berry Genomics has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Qiming Venture Partners and Legend Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital investments are directed toward multiple sectors. | 2006 | qimingvc.com | Shanghai, China | |
Venture Capital firm focused on multiple sectors | – | legendcapital.com.cn | Haidian, China |
Investor details for Berry Genomics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
IPO & Listings of Berry Genomics
Berry Genomics is a publicly listed company on the SZSE with ticker symbol 000710 in China, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date25 Dec 2016
- Listed onSZSE: 710
- Listed entityBerry Genomics Co. Ltd. Class A
- Exchange sectorHealth technology
- ISINCNE000000PN7
- Share price11.30 CNY (+10.03% on the day) · 2026-10-09
- Market capitalisation3,619,528,899.00 CNY
- EPS (diluted, trailing year)-0.60 CNY
- Volume (last session)76,711,338
Financials of Berry Genomics
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 927.7M CNY | -196.8M CNY | -78.6M CNY |
| 2024 | 1.07B CNY | -192.4M CNY | -21.4M CNY |
| 2023 | 1.15B CNY | -427.2M CNY | -76.2M CNY |
| 2022 | 1.36B CNY | -248.9M CNY | -11.7M CNY |
| 2021 | 1.41B CNY | -110.8M CNY | 63.1M CNY |
Detailed financial statements for Berry Genomics
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Berry Genomics
4 dated milestones of Berry Genomics across 6 years, from founding to its latest funding, stage changes and deals.
- Founded Berry Genomics is founded.
- Funding First funding round.
- Funding Latest funding round, Series B, of $16.0M.
- IPO Lists on the stock exchange (IPO).
Competitors of Berry Genomics
Berry Genomics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Natera, SYNLAB, Rejuvenate Bio, Novogene Corporation and Progenity, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| natera.com | 2004 | Redwood, United States | $152.1M | 3,293 | Developer of cell-free DNA testing for oncology, women’s health, and organ health | |
| synlab.com | 1998 | Munich, Germany | – | 28,693 | Provider of medical diagnosis and clinical laboratory analysis services | |
| rejuvenatebio.com | 2017 | San Diego, United States | $14.58M | 39 | Gene-editing platform and anti-aging therapy for dogs are developed. | |
| novogene.com | 2011 | Beijing, China | $75M | 141 | Genomic services and solutions with NGS expertise are provided. | |
| progenity.com | 2011 | San Diego, United States | $216.63M | 125 | Non-invasive prenatal genomic testing is provided for genetic disorders. | |
| clinical-microbiomics.com | 2016 | Horsholm, Denmark | $9.71M | 35 | Meta-genomics platforms and services for microbiome studies are provided. | |
| bgi.com | 1999 | Shenzhen, China | – | 25 | BGI is engaged in genomics and precision medicine solutions. | |
| genewiz.com | 1999 | South Plainfield, United States | – | 452 | Genomic services are provided for the life sciences industry. | |
| sequenom.com | 1994 | San Diego, United States | – | 524 | Noninvasive prenatal testing using cell-free fetal nucleic acids is offered. | |
| ariosadx.com | 2008 | San Jose, United States | $67.5M | 246 | Molecular diagnostics for prenatal genetic testing are specialized in. |
Detailed competitors of Berry Genomics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Berry Genomics
The website of Berry Genomics (berrygenomics.com) receives about 35.4K visits a month and ranks #787,850 among all websites worldwide, #931 in Biotechnology and Pharmaceuticals.
- Monthly visits35.4K
▼ 2.3% vs previous month
- Unique visitors2.3K
per month
- Global rank#787,850
among all websites
- Category rank#931
Health · Biotechnology and Pharmaceuticals
- Bounce rate15%
- Pages per visit7.2
- Average visit23 min 21 sec
- DevicesDesktop 98% · Mobile 2%
Websites whose visitors overlap most with Berry Genomics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| admerahealth.com | 100% | 6.6K | #3,477,831 | View details | |
sg120.com | sg120.com | 56% | – | – | – |
globecancer.com | globecancer.com | 53% | – | #9,563,658 | – |
Latest news on Berry Genomics
Complete news archive for Berry Genomics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Berry Genomics
10 companies that operate in the same segment as Berry Genomics (Genomics & Gene Therapy Platforms), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 2,020 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 3.22 B | USD 147.17 M | 1,000 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits | 2006 | Sunnyvale, California, United States | USD 943.53 M | USD 189.9 M | 265 | |
Provider of DNA testing services to create a family tree and ancestor | 2003 | Yehud, Central District, Israel | USD 40 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Provider of an online genealogy platform offering a host of services | 1996 | Lehi, Utah, United States | USD 146.2 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Berry Genomics
Berry Genomics was founded in 2010 and raised its 1st funding round 1 year after it was founded.
Berry Genomics is headquartered in Beijing, China.
Berry Genomics is a funded company, having raised a total of $16M across 3 funding rounds to date.
Berry Genomics has 1,400 employees.
Annual revenue of Berry Genomics is $132.51M as on Dec 31, 2025.
Biotech company that develops and commercializes next-generation sequencing based integrated solutions for clinical applications. Focuses majorly on genetic testing and oncology testing. It is one of the leading providers of non-invasive prenatal testing (NIPT) in China. Its products include NextSeq CN500 gene sequencing platform and supply of consumables to the sequencing system. In Dec 2016, the company went public on Chinas Shenzhen market via a reverse merger with Chengdu Tianxing Instrument Meter, a shell auto company, in a deal that values Berry Genomics at 618.8M.
Berry Genomics's top competitors include Natera, Novogene Corporation and BGI.
Yes, Berry Genomics is publicly traded on SZSE under the ticker symbol 000710.
Berry Genomics has 2 investors. Key investors include Qiming Venture Partners, and Legend Capital.